Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
The groundbreaking SPF technology is specifically designed and formulated to prevent sunburn or sun damage while allowing the passage of sufficient UVB light that our bodies use to naturally produce vitamin D
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
Subscribe To Our Newsletter & Stay Updated